HMO expansion: Jennewein Biotechnologie to strengthen portfolio with Arthus Mineralsprings facility buy

636746672521628005236164793_ScreenHunter 400.png

09 0ct 2018 --- Jennewein Biotechnologie is to expand its production of human milk oligosaccharides (HMO) from its current portfolio of two products to include five more. The expansion is facilitated through the company's acquisition of the former facilities of Arthus Mineralsprings in Bad Hönningen, Germany. Jennewein plans to build a new integrated fermentation and recovery plant for the production of HMOs.

“With the new plant, we will be able to produce additional HMOs, expanding our current portfolio of two products (2′ fucosyllactose and lacto-N-neotetraose) to include five more (3′ fucosyllactose, difucosyllactose, lacto-N-tetraose, 6′-sialyllactose and 3′-sialyllactose),” says Benedikt Engels, Chief Operation Officer at Jennewein.

“We have been searching for some time for a suitable location to establish an integrated HMO fermentation and recovery plant close to our current facility in Rheinbreitbach,” says Dr. Stefan Jennewein, CEO and Co-Founder of the company.

Click to Enlarge
Jennewein Biotechnologie hopes to expand its HMO
portfolio from two to five ingredients.

HMOs form the third most abundant solid component of human milk after lactose and fat and research increasingly demonstrates that much of breast milk's value lies within these components. HMOs have prebiotic properties and are incredibly complex to replicate, but are increasingly sought after in infant nutrition products.

Jennewein will continue to focus on the infant and medical nutrition markets, but a spokesperson for the company tells NutritionInsight that the option for developing products in the adult nutrition area may be a future possibility too. 

The new integrated facility will combine fermentation and recovery, and will yield spray-dried HMO products. Jennewein Biotechnologie plans to build separate production lines for the manufacture of each of the new HMO products.

“The new plant will become one of the largest fermentation facilities in central Europe,” adds Stephan Michel, Chief Financial Officer.

Jennewein Biotechnologie is an international industrial biotechnology company with a range of products in the field of complex oligosaccharides (HMOs) and rare monosaccharides. 

In 2015, the US Food and Drug Administration (FDA) granted a license to market 2′-fucosyllactose in the US. This was followed in 2017 by European Union marketing authorization under the Novel Food Regulation.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Resilient in nutrition: DSM reports “very strong” 2018, reveals €1 billion buyback strategy

14 Feb 2019 --- DSM has reported a “very strong year,” including robust Q4 figures, organic sales growth of 6 percent and adjusted EBITDA up 26 percent, including €290 million (US$327 million) due to temporary exceptional vitamin effects. With Q4 core profit topping expectations, the company has announced that it will buy back €1 billion in shares.

Health & Nutrition News

DMK inaugurates new US$164m high-tech infant nutrition plant in Germany

08 Feb 2019 --- German dairy cooperative DMK yesterday inaugurated a new plant in Strückhausen, Germany. Featuring cutting-edge technology, DMK reports the facility will be used solely for the production of infant nutrition, such as its Humana brand. DMK has invested €145 million (US$164 million) in converting the site into a “state-of-the-art” facility. The company hopes to also boost the economy of the Lower Saxony region and create local job opportunities.

Health & Nutrition News

Weekly roundup: Lonza expands Canadian distribution agreement with Quadra, BioIberica introduces corporate rebranding

08 Feb 2019 ---This week in nutrition, Lonza expanded its distribution agreement with Quadra Chemicals Ltd (Quadra) in Canada. Probiotic brand Culturelle and Persona Nutrition have partnered to deliver the Culturelle probiotic through Persona’s personalized nutrition program. ESI Nutrition – Laïta’s new nutrition division – is highlighting its capabilities in the MENA region to develop and launch infant nutrition products. Lastly, Nuherbs is marking its 40th year as an importer of Chinese herbal formulas and premium Chinese herbs.

Health & Nutrition News

Microbiome research advance for China’s baby food market: Jennewein and Yili form HMO partnership

06 Feb 2019 --- Jennewein Biotechnologie, which specializes in the research and manufacture of human milk oligosaccharides (HMO), and Inner Mongolia Yili Industrial Group (Yili Group), China’s leading dairy company, have signed a Memorandum of Understanding on research into infant microbiome and HMOs. Their goal will be to develop an innovative infant formula and dairy products specifically tailored to the Chinese market – the largest market for baby food globally.

Health & Nutrition News

Hong Kong researchers boost DHA absorption with novel nano-encapsulation

04 Feb 2019 --- Researchers at the Hong Kong Polytechnic University (PolyU) have developed a new nano-encapsulation technology that optimizes the absorption of DHA. The researchers used Zein – an edible corn protein – to mimic milk fat globule membrane (MFGM), prevent DHA from oxidation and increase its absorption. The encapsulation method can reportedly be used to increase absorption in nutrient delivery.

More Articles
URL : http://www.nutritioninsight.com:80/news/jennewein-biotechnologie-to-expand-hmo-portfolio-with-acquisition-of-further-facilities.html